Brian Lehmann
Last active: 9/15/2015

  1. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT (2013) Clin Cancer Res 19(19): 5533-40
    › Primary publication · 23948975 (PubMed) · PMC3813597 (PubMed Central)
  2. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y (2013) Biomed Res Int : 915636
    › Primary publication · 24303503 (PubMed) · PMC3835197 (PubMed Central)
  3. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W (2013) Clin Cancer Res 19(24): 6696-702
    › Primary publication · 24345920 (PubMed) · PMC3880773 (PubMed Central)
  4. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL, Yi Y (2013) PLoS One 8(1): e54979
    › Primary publication · 23383020 (PubMed) · PMC3558433 (PubMed Central)
  5. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA (2012) Cancer Inform : 147-56
    › Primary publication · 22872785 (PubMed) · PMC3412597 (PubMed Central)
  6. Targeting mutant p53 in human tumors. Lehmann BD, Pietenpol JA (2012) J Clin Oncol 30(29): 3648-50
    › Primary publication · 22965952 (PubMed)
  7. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA (2012) Cell Cycle 11(24): 4579-88
    › Primary publication · 23187804 (PubMed) · PMC3562303 (PubMed Central)
  8. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) J Clin Invest 121(7): 2750-67
    › Primary publication · 21633166 (PubMed) · PMC3127435 (PubMed Central)
  9. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA (2011) Oncotarget 2(8): 610-26
    › Primary publication · 21881167 (PubMed) · PMC3248208 (PubMed Central)
  10. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA (2010) Breast Cancer Res 12(3): R41
    › Primary publication · 20576088 (PubMed) · PMC2917036 (PubMed Central)